The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026. ・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.

View Butterfly Network, Inc. Class A BFLY stock quote prices, financial information, real-time forecasts, and company news from CNN.

Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts in 2026 for investors to watch.

View Integra LifeSciences Holdings Corporation IART stock quote prices, financial information, real-time forecasts, and company news from CNN.

Idiopathic Membranous Nephropathy Market Is Predicted To Reach USD 1 Billion By 2036 Due To Rising Therapeutic Options ...

Learn more about whether Relay Therapeutics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

A year after revealing his “Liberation Day” trade policy initiatives, U.S. President Donald Trump is set to announce tariffs ...

Travere Therapeutics is awaiting an FDA decision on a label expansion for FILSPARI in focal segmental glomerulosclerosis, a ...

View Praxis Precision Medicines, Inc. PRAX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

According to TipRanks.com, Skor is a 4-star analyst with an average return of 15.8% and a 61.2% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.